Veracyte, Inc. (VCYT)

Market Cap	1.44B
Revenue (ttm)	361.05M
Net Income (ttm)	-74.40M
Shares Out	75.07M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	764,148
Open	18.75
Previous Close	18.86
Day's Range	18.61 - 19.35
52-Week Range	18.61 - 30.52
Beta	1.64
Analysts	Buy
Price Target	29.00 (+51.04%)
Earnings Date	May 2, 2024

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 815
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT

Financial Performance

In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $29.0, which is an increase of 51.04% from the latest price.

Price Target

$29.0

(51.04% upside)

Analyst Consensus: Buy